Novo Nordisk Raises Earnings Forecast on Weight-Loss Drug Demand, Shares Dip

Novo Nordisk's quarterly profit exceeded expectations, driven by strong demand for its weight-loss drugs like Wegovy. The company raised its full-year outlook, though its stock saw a decline.